Clinical trials: COVID-19; Immunity
SARS-CoV-2 Viral Kinetics and Host Immune Responses
Understanding COVID-19
This single-center prospective observational study will examine immune responses to to SARS-CoV-2 and how they correlate with its virological characteristics and clinical manifestations in infected patients.
- Trial name
- NCT04329546
- Testing
- NA (no intervention)
- Where
- Switzerland
- Volunteers
- 86 people
- Sponsor
- University Hospital, Geneva
SARS CoV 2 Infection, COVID-19
Sars-COV-2 (COVID-19) Immunity in immunoCOmpromised Populations
The immune response of COVID-19 vaccination was monitored and studied in the context of the previously PICOV study (P2020/424), Nephro- VAC studies (P2020/284 and P2020/312) and Lung-VAC study (P2021/182).
- Trial name
- COVICO (NCT05667597)
- Testing
- Humoral immunity
- Where
- Belgium
- Volunteers
- 350 people, healthy volunteers welcome
- Sponsor
- Maria Goossens
Corona Virus Infection, Flu Vaccine
Understanding Immunity to the Flu Vaccine in COVID-19 Patients
The purpose of this study is to measure immunity to the flu vaccine over time in patients who have had COVID-19 and may have other medical conditions including obesity, type 2 diabetes, chronic fatigue, or long-term COVID-19…
- Conditions
- Corona Virus Infection, Flu Vaccine, Immunity
- Trial name
- NCT04579588
- Testing
- Flu shot
- Where
- United States
- Volunteers
- 230 people, healthy volunteers welcome
- Sponsor
- Stanford University
COVID-19
COVID-19 Immunity Assessment
The purpose of this study is to collect blood specimens from individuals post infection or post vaccination over time to assess COVID19 Immunity.
- Trial name
- NCT05080231
- Where
- United States
- Volunteers
- 662 people, healthy volunteers welcome
- Sponsor
- DxTerity Diagnostics
Covid19, SARS-CoV2 Infection
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent Vaccine
The purpose of this study is to evaluate the safety and efficacy of mRNA COVID-19 vaccines in: People with prior COVID-19 (SARS-CoV-2 infection) who were in the ACTIV-2/A5401 study.
- Trial name
- NCT04952402
- Testing
- Study-provided Moderna mRNA-1273 COVID-19 vaccine, Community-provided Moderna mRNA-1273 COVID-19 Vaccine, Community-Provided Pfizer-BioNTech BNT162b2 COVID-19 Vaccine
- Where
- 6 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
Immunoglobulin G Antibody Immune Response Profile Following Infection With SARS-CoV-2 in COVID-19 Egyptian Patients
The objective of this study is to detect the evidence on the immune response following acute SARS-CoV-2 infections. the study will report the profile of IgG specific antibodies levels to SARS-CoV-2 infection found in recovered…
- Trial name
- COVID-19 (NCT04483622)
- Where
- Egypt
- Volunteers
- 33 people
- Sponsor
- Sohag University
Follicular Lymphoma
Prospective Biological Study to Evaluate the Persistence of COVID-19 Vaccine and Other Vaccines'-Induced Immune Responses in Follicular Lymphoma Patients Undergoing Frontline Induction Immuno-chemotherapy and Anti-CD20 Maintenance
This is a prospective biological study evaluating the persistence of COVID-19 vaccine and other vaccines' (zoster, diphtheria and tetanus)-induced immunity in a subgroup patient affected by Follicular Lymphoma requiring treatment…
- Trial name
- FIL_FollVax22 (NCT06070961)
- Testing
- Cellular immunity vs SARS-CoV-2, Humoral immunity vs SARS-CoV-2, Cellular immunity vs Varicella Zoster Virus
- Where
- 14 sites in Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione Italiana Linfomi - ETS
Covid19
Local and General Immune Response After Coronavirus Disease (COVID-19) Vaccination in Volunteers
This study aims to gain more insight in the immunological characteristics and immune response on a local level (the nose) and systemic level (the blood) of healthy people vaccinated with the current available COVID-19 messenger…
- Trial name
- COVACC2 (NCT04996238)
- Testing
- Blood and nasal fluid sampling before and after COVID-19 vaccination
- Where
- Belgium
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
COVID-19
Reducing COVID-19 Related Hospital Admission in Elderly by BCG Vaccination
Bacillus Calmette-Guérin (BCG) vaccine not only protects against tuberculosis, but has also been shown to induce protection against various infections with a viral aetiology, leading to significant reductions in morbidity and…
- Trial name
- NCT04417335
- Testing
- BCG vaccine
- Where
- 2 sites in Netherlands
- Volunteers
- 2,014 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
COVID-19 Respiratory Infection
CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients
T-cell exhaustion may limit long-term immunity in COVID-19 patients. T cells can lose their ability to fight viruses and tumors when they have prolonged exposure to these enemies.
- Trial name
- NCT04990557
- Testing
- PD-1 and ACE2 Knockout T Cells
- Volunteers
- 16 people
- Sponsor
- Mahmoud Ramadan mohamed Elkazzaz
Immunization
Adjuvant Effect of Physical Exercise on Immune Response to COVID-19 Vaccination and Interactions With Stress
The purpose of this study is to evaluate the extent to which a single session of light to moderate intensity exercise performed within 30 minutes after receiving either the initial dose of COVID-19 mRNA vaccine may modify the…
- Trial name
- NCT05213000
- Testing
- Exercise
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Iowa State University
Diabetes Mellitus, Type 1
Anti-viral Action Against Type 1 Diabetes Autoimmunity
The study GPPAD-05 AVAnT1A is a phase 4 clinical trial intending to enroll 2252 children, who will be randomly assigned to receive COVID-19 vaccination (Comirnaty® 3 μg Omicron XBB.1.5 or new variant Comirnaty vaccines ) or…
- Trial name
- NCT06452654
- Testing
- Comirnaty Injectable Product, Sodium Chloride 0.9% Inj
- Where
- 9 sites in Austria, Belgium and 3 more
- Volunteers
- 2,252 people, healthy volunteers welcome
- Sponsor
- Technical University of Munich
Coronavirus Disease 2019
Immunogenicity and Safety Evaluation of Recombinant Novel Coronavirus Vaccine (CHO Cells) in Enhancing Immunity
Popular topic: Clinical study on immunogenicity and safety evaluation of sequentially enhanced immunity with recombinant Novel Coronavirus vaccine (CHO cells) Research purpose:Main purpose:To evaluate the immunogenicity of…
- Trial name
- NCT05089045
- Testing
- Recombinant new coronavirus vaccine (CHO cell) group
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Allergy and Immunology, Infection Viral
Evaluation of Immune Response in COVID-19 Patients
The aim of the project is to evaluate the immunological features of COVID-19 patients. Patients are recruited without any pharmacological treatments restriction.
- Trial name
- IMMUNOVID (NCT04438629)
- Testing
- COVID-19 treatment
- Where
- Italy
- Volunteers
- 80 people
- Sponsor
- Azienda Ospedaliera Universitaria Integrata Verona
COVID-19
Efficacy of Different COVID-19 Vaccine Combinations in Inducing Long-term Humoral Immunity [PRIBIVAC]
PRIBIVAC will assess a heterologous prime-boost-boost strategy in comparison with a homologous regimen in order to compare short and long-term immunogenicity of different COVID-19 vaccine combinations against the ancestral…
- Trial name
- PRIBIVAC (NCT05142319)
- Testing
- Homologous mRNA booster vaccine, Heterologous mRNA booster vaccine, COVAXIN
- Where
- Singapore
- Volunteers
- 326 people, healthy volunteers welcome
- Sponsor
- Tan Tock Seng Hospital
COVID-19, SARS-CoV-2
Dynamics of the Immune Response to COVID-19 / Infection by SARS-CoV-2
To evaluate host-immune biomarkers including TRAIL, IP-10, CRP and their computational integration for predicting COVID-19 and disease severity in patients with PCR-confirmed COVID-19.
- Conditions
- COVID-19, SARS-CoV-2, Viral Infection
- Trial name
- DIRECTOR (NCT04655521)
- Where
- Germany
- Volunteers
- 173 people, healthy volunteers welcome
- Sponsor
- Universität des Saarlandes
COVID-19
Predictive Immune Biomarkers for COVID-19 Pathogenesis
The spectrum of the COVID-19 disease ranges from benign to asymptomatic to viral pneumopathy that can progress to acute respiratory distress syndrome (ARDS).
- Trial name
- COVIDBioToul (NCT04385108)
- Testing
- Blood collection on admission and longitudinally, Blood collection on their first consultation and 10 to 14 days later
- Where
- France
- Volunteers
- 565 people
- Sponsor
- University Hospital, Toulouse
Influenza, SARS-CoV-2 (COVID-19) Infection
Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2
The purpose of this study is to evaluate the virus-specific immune response in people who are symptomatic with confirmed influenza or COVID-19.
- Conditions
- Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host
- Trial name
- WU 437 (NCT06848309)
- Testing
- Bronchoscopy
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Prevention of COVID19
Immunogenecity and Safety of VaccinemRNA-1273 in Elderly Volunteers (Over 65 y) Compared to Younger Ones (18-45y)
This study aims to evaluate the immunogenicity of Moderna mRNA-1273 vaccine in volunteers aged 65 years or more compared to volunteers aged 18-45 years, over 24 months duration.
- Trial name
- CoviCompareM (NCT04748471)
- Testing
- mRNA-1273
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19, SARS-CoV-2
Study Will Assess the Safety, Neutralizing Activity and Efficacy of AZD3152 in Adults With Conditions Increasing Risk of Inadequate Protective Immune Response After Vaccination and Thus Are at High Risk of Developing Severe COVID-19
AZD3152, a single mAb, is being developed to have broad neutralizing activity across known SARS-CoV-2 variants of concern for pre-exposure prophylaxis of COVID-19.
- Trial name
- NOVELLA (NCT06057064)
- Testing
- Biological: AZD3152
- Where
- 6 sites in Russia
- Volunteers
- 116 people
- Sponsor
- AstraZeneca